ReviewMicrobial biotechnology2024
Unlocking the potential of bacterial endophytes from medicinal plants for drug discovery.
Review in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Plant-Endophyte Cross-Talk inMicroorganisms · 2026Article
- Herbal extracts as antibiotic adjuvants against ESKAPE pathogens: mechanisms and therapeutic potential.Engineering microbiology · 2026Review
- Unlocking the potential of endophytes in enhancing plant secondary metabolite biosynthesis.Biochemistry and biophysics reports · 2026Review
- Network pharmacological prediction on metabolites of dominant endophytic strains fromFrontiers in microbiology · 2026Article
- Analysis of microbial diversity inFrontiers in microbiology · 2026Article
- BSocial Tool Deciphers Highly Functional Plant Growth-Promoting Bacterial Consortia.Microbial biotechnology · 2025Article
- Anticancer Activity of Endophytic Bacterial Extracts from Potentilla supina in HepG2 and HCT116 Cells.Current microbiology · 2025Article
- Secondary Metabolite Biosynthesis Potential ofACS omega · 2025Article
- Dibohemamines I-O from Streptomyces sp. GZWMJZ-662, an endophytic actinomycete from the medicinal and edible plant Houttuynia cordata Thunb.Natural products and bioprospecting · 2025Article
- In vitro and In silico investigation deciphering novel antifungal activity of endophyte Bacillus velezensis CBMB205 against Fusarium oxysporum.Scientific reports · 2025Article
- Recent advances in Polygonaceae endophytes: diversity, secondary metabolites and biotechnological applications.Frontiers in bioengineering and biotechnology · 2025Review
- Antibiotic-producing plant-associated bacteria, anti-virulence therapy and microbiome engineering: Integrated approaches in sustainable agriculture.Microbial biotechnology · 2024Article
- Genomic characterization and identification of candidate genes for putative podophyllotoxin biosynthesis pathway in Penicillium herquei HGN12.1C.Microbial biotechnology · 2024Article
- High-throughput sequencing-based analysis of the composition and diversity of the endophyte community in roots of Stellera chamaejasme.Scientific reports · 2024Article
- Unlocking the potential of bacterial endophytes from medicinal plants for drug discovery.Microbial biotechnology · 2024Review
- Genomes and secondary metabolomes ofFrontiers in microbiology · 2024Article
- Insights on mining the pangenome ofFrontiers in microbiology · 2024Article
- Elucidating the endophytic bacterial and fungal community composition and diversity in the tree fernFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Among the plant-associated microorganisms, the so-called endophytes continue to attract much attention because of their ability not only to protect host plants from biotic and abiotic stress factors, but also the potential to produce bioactive secondary metabolites. The latter property can elicit growth-promoting effects on plants, as well as boost the production of plant-specific secondary metabolites with valuable pharmacological properties. In addition, endophyte-derived secondary metabolites may be a rich source for the discovery of drugs to treat various diseases, including infections and cancer. However, the full potential of endophytes to produce bioactive secondary metabolites is often not revealed upon conventional cultivation in the laboratory. New advances in genomics and metabolic engineering offer exciting opportunities for the exploration and exploitation of endophytes' biosynthetic potential. This review focuses on bacterial endophytes of medicinal plants, some of their secondary metabolites and recent advances in deciphering their biosynthesis. The latter may assist in genetic engineering efforts aimed at the discovery of novel bioactive compounds with the potential to be developed into drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.